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Abstract
Objective
Glutaricaciduria type 1 (GA1), is a rare, treatable neuro metabolic 
disease, due to glutaryl- CoA dehydrogenase (GCDH) gene mutation.In 
regions without neonatal blood screening (NBS), patients are diagnosed 
in symptomatic period. This study was carried out to assess patients with 
GA1 for clinical, biochemical, neuroimaging findings and GCDH gene 
mutations analysis.
Materials & Methods
In this cross-sectional study, clinical manifestation, neuroimaging and 
metabolic findings of eleven Iranian GA1 patients of MofidChildren’s 
Hospital, Tehran, Iranbetween 2001 and 2011,were evaluated.Mutational 
analysis of the GCDH gene was performed on genomic DNA. Genomic 
DNA was extracted from peripheral lymphocytes using QIAamp DNA 
Micro Kit (Qiagen). All 11 exons and flanking intronic regions of the 
GCDH gene were amplified by polymerase chain reaction (PCR). 
Results
All patients were diagnosed before 32 months old. Clinical presentations of 
GA1 include acute encephalopathic crisis and/or developmental delay and 
macrocephaly. Seven GCDH gene mutations were detected in our patients. 
The most frequent GCDH mutations occurred in exon7 then exon8, 10 
and11. G244 C in exon7, R294 Q in exon8 and N373 S in exon 10 were 
three novel mutations. There was no correlation between of genotype and 
phenotype in our patients.
Conclusion
Physician must remember GA1 in differential diagnosis of acute 
encephalopathic crisis, macrocephaly, developmental delay, movement 
disorders such as dystonia and dyskinesia. Early detection, proper treatment 
and selective screening of patients’ siblings can prevent neurologic 
disabilities.
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Materials & Methods
We studied 11Iranian patients with GA1 previously 
diagnosed in Neurology and Endocrinology Clinics 
of MofidChildren’s Hospital, Tehran, Iranbetween 
2001 and 2011.Fourteen Iranian GA1 patients were 
diagnosed during these 10 yr.One patient died. One 
family did not accept to test their child for GCDH gene 
mutation. One patient’s family immigrated to another 
country. Diagnoses of these symptomatic patients 
were based on glutarylcarnitine analysis in their dried 
blood spots or urine and/or their urinary organic acid 
profiles. They were invited to hospital for interview, 
physical examination, collecting their urine and blood 
laboratory information, neuroimaging findings and 
performing GCDH gene mutation study. GCDH gene 
mutation studies were done in Special Medical Center, 
Tehran, Iran.
Mutational analysis of the GCDH gene was performed 
on genomic DNA. Genomic DNA was extracted from 
peripheral lymphocytes using QIAamp DNA Micro 
Kit (Qiagen). All 11 exons and flanking intronic 
regions of the GCDH gene were amplified by PCR. 
Primer sequences are given in Table 1 (13). PCR was 
performed in a total volume 25 µl containing1x PCR 
buffer,1.5mM MgCl2, 8 pmol each primer, 0.2 mM each 
dNTP, 50 ng template DNA, and 0.3 U Taq polymerase 
(SinaClon, Iran). Five percent DMSO was also added 
for PCR of exon 2.Amplification was performed with 
initial denaturation at 94ºC for 5 min,32 cycles of 1 
min at 94ºC, 1 min at 55-62ºC atannealing according to 
Table 1, and 1 min at 72ºC and final extension were 5 
min at 72ºC. The PCR products were sequenced on ABI 
3700 sequencer (Kosar Company, Tehran).Sequencing 
results were compared with ref sequences in NCBI.
Informed consent to perform DNA analysis wasobtained 
from the parents of the patients. The Ethics Committee 
of the Faculty of Medicine,ShahidBeheshti University 
of Medical Sciences, Tehran, Iran approved our study 
protocol. 
Results
The clinical and molecular findings of 11 Iranian GA1 
patients are summarized in Table 1.
Introduction
Glutaricaciduria type 1(GA1, #231670) was introduced 
as a new neurodegenerative disorder in 1975 (1). This 
progressive neurometabolic disorder with characteristic 
clinical presentation usually manifests with macrocephaly, 
acute encephalopathic crisis after upper respiratory/
gastrointestinal infection,fever, dehydration, vaccination 
orin lesser extent with insidious-onsetpresentation such 
as movement disorder (dystonia, ataxia ), developmental 
delay(2-4).Occasionally child physical abuse has been 
suspected because of presence of subdural effusions 
(5). Life expectancy is greatly reduced in symptomatic 
patients with complex movement disorder (6).The peak 
age of presentation is 9 months and most symptomatic 
patients present before 3 yr of age; althoughrare 
symptomatic neurological presentation (late onset) are 
reported after 5 yr old of age(7,8). 
Frequent neuroimaging findings in GA1 are described 
in the different medical literature include widened 
Sylvianfissures, frontotemporal volume loss, 
ventriculomegaly, subdural hematomas, delayed 
myelination demyelination and basal ganglia lesions 
(9,10).
Deficient activity of mitochondrial enzyme glutaryl-
CoA dehydrogenase (GCDH; EC.1.3.99.7) that is 
essential for degradation of lysine, hydroxylysine and 
tryptophan pathway is responsible for this autosomal 
recessive disorder of inborn error of metabolism. Thus, 
the biochemical diagnosis is based on detection of 
increased levels glutaric acid, 3-hydroxyglutaric acid 
in urine, other physiologic body fluid and elevation 
glutarylcarnitine (C5DC) level in plasma or urine (11). 
Suspected GA1 patients based on clinical, biochemical, 
neuroimaging finding is confirmed by GCDH gene 
mutations or GCDH enzyme activity.
GCDH gene encodes GCDH enzyme located on 
chromosome19p13.2and is composed of 11 exons and 
10 introns (12, 13).More than 200 mutations have been 
reported in the GCDH gene (14). However,some GCDH 
gene mutations are frequent in specific population.
This study was carried out to assess patients with GA1 
for clinical, biochemical, neuroimaging findings and 
GCDH gene mutations analysis.
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Demographic and clinical findings
Eleven symptomatic Iranian patients with GA1 were 
diagnosed from 10 families. The only sibling patients 
were two brothers, delivered as triple pregnancy. All of 
patients were offspring of consanguineous marriages.
Ethnic origin and gender frequency ofour patients are 
shown in Figure 1.
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Fig1. Frequency of patients with GA1 according to gender and ethnicity
Fig2. Axial T2 weighted MRI scan of patient 11 shows 
basal ganglia (putamen) hyperintensities
The mean age at diagnosis was 14.8 (range: 5-32) 
months. The mean age at study time was 44.5 (range 
15-102) months. Acute encephalopathic crisis and 
seizure following URI or vaccination were the first 
clinical presentations in six cases. Macrocephaly, 
developmental delay and extrapyramidal signs were 
the first presentations in other five patients. Birth head 
circumferences of all patients were under percentile 
95(percentile25-90).Patients were treated by low 
protein (lysine,tryptophan,etc.) diets and carnitine 
supplementation. Treatments were discontinued in 
five patients because their families did not fill any 
improvement in their child symptoms and signs. Other 
families tried to continue this treatment, although these 
patients were diagnosed, recently.
Neuroimaging findings
Included widened Sylvian fissure in 100%, bitemporal 
arachnoid cysts in 60%, white matter signal changes in 
33% and basal ganglia lesions in 27% of 25 times brain 
neuroimaging. Neuroimaging studies include16brain CT 
scan and 9brainsMRI in eleven patients (Figure 2-4). 
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Metabolic analysis finding
Our patients’ diagnoses were based on blood and/or urine 
analysis. Bloodglutarylcarnitine and glutarylcarnitine/
free carnitine ratio were increased in 11 patients. Urines 
of 5 patients were tested for organic acid. Increased 
excretions of glutaric acid and/or 3-hydroxyglutaric acid 
(organic acids) were reported in these 5 patients.
GCDH mutation
We found 7 GCDH gene mutations in eleven patients, 
three of them were not reported before. Five (45%) 
patients had mutations in exon 7.P 248 L mutation in 
exon 7 was detected in 3(27%) patients.Three novel 
mutations were G244C (exon7), A294P (exon8) and 
N373SMutation in exon10.Four different mutations 
were seen in 6 Turkish patients. More information about 
GCDH mutations is shown in Table1, too.
Discussion
Heterogeneous clinical manifestations, biochemical 
findings, and GCDH gene mutations are seen in GA1. A 
severe and treatable inborn error of metabolism usually 
diagnosed in some countries in neonatal period through 
expanded newborn screening programusing analysis of 
glutarylcarnitine in dried blood spots by tandem mass 
spectrometry(15,16). In areas without newborn screening 
for acylcarnitine profile such as Iran at present, patients 
Glutaric AciduriaType 1: Clinical and Molecular Study in Iranian Patients, 3 Novel Mutations
with GA1 usually are diagnosed in symptomatic period or 
as a selective screening in siblings of a known GA1 patient 
(17). In most neonates diagnosed withpresymptomatic 
neonatal period, striatal necrosis and movement disorder 
can be prevented by low lysine diet and carnitine 
supplementation (18). An emergency treatment protocol 
in catabolic states such as fever, gastroenteritis, surgery, 
immunization, including natural protein stopping, 
proper hydration, increase carnitine supplementation, 
appropriate glucose and caloric supply, brisk alkaline 
urine output, proper antibiotics and antipyretic drugs also 
are important to prevent neurological sequels(19,20). 
Acute encephalopathic crisiswas observed as equally as 
insidious presentation (developmental delay dystonia) in 
our patients. Acute encephalopathic crisis was reported 
in majority of patients with GA1 (4) and most patients 
were presented insidious with developmental delay, 
macrocephaly (21,22). The discrepancy is due to likely 
different factors such as the misdiagnosis of initial acute 
crises by poorly trained physicians or perhaps different 
GCDH gene mutations.
Enlarge head circumference was described in most 
neonates with GA1 as the only early sign of this disorder 
(19).Macrocephaly (occipito-frontal circumference 
above 95 percentile) was not present at birth in our 
patients. However, macrocephaly was observed at 
interview time in our seven (63%) patients.
Fig3.Axial T2 weighted MRI scan of patient 4 shows 
frontotemporal brain atrophy, temporal hypoplasia, 
white matter hyperintensities
Fig4.Chronal T2 weighted MRI in patient 7 shows 
bitemporal arachnoid cysts
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Dietary management was not continued in five of our 
severe disabled patients because they did not fill any 
improvement with this type of therapy. No detectable 
beneficial effects of long-term dietary treatment were 
reported in patients with obvious neurological symptoms 
(6). Although strict low lysine diet is recommended 
especially in asymptomatic patients up to age of 6 yr old, 
continuing less strict diet therapy is advised after 6 yr 
old, too. Carnitine supplementation must be continued 
lifelong (23). Detection of patients in asymptomatic 
period and appropriate prospective care reduces clinical 
and neuroimaging presentation of basal ganglia injury 
from90% to 35% (19).
Our patients’ neuroimaging findings showed widened 
Sylvian fissure (bat wing sign) in all patients. Widened 
Sylvian fissure as characteristic but not pathogenomic 
neuroimaging finding was reported in 93% of 
neuroimaging in symptomatic GA1 patients (9).This 
finding is reported in asymptomatic patients detected 
on expanded newborn screening suggestive temporal 
hypoplasia rather than frontotemporal atrophy (10).
White matter abnormalities were detected in 33% of 
our patients’ brain neuroimaging. White matter changes 
did not correlate with clinical manifestation. Abnormal 
white matter changes in Amish patients were reported 
less frequently (6%) than non-Amish patients (32%). 
The exact mechanism of this abnormal signal is not 
understood (19). We found basal ganglia involvement 
in 27% of neuroimagings of patients. Acute striatal 
necrosis was reported as the major cause of movement 
morbidity and mortality in GA1 patients. Nutritional and 
pharmacological management of newborn detected in 
expanded newborn screening in asymptomaticperiod-
reduced incidence of striatal injury. However, it is 
unclear why despite early asymptomatic detection of 
GA1 patients and treatmentintervention; approximately 
one-third ofthem developed striatal injury (19).
Usually suspected GA1 patients based on clinical, 
neuroimaging, biochemical findings areconfirmed by 
molecular or enzymatic study. GCDH gene mutation 
is used to confirm GA1, carrier detection, genetic 
consultation and prenatal diagnosis of this disorder. 
To date, more than 200 mutations in GCDH gene 
have been reported. Some mutations are frequent in 
specific populations. In Ojibway-Cree linguistic group 
patients in Manitoba and northwest of Ontario IVS1+5 
G > T mutation is prevalent (24). In North Carolina, 
homozygous mutation E404K (1240 G> A) in exon 10 
was reported (25).Selective screening of common gene 
mutation could be a useful way to decrease time and cost 
of molecular gene analysis.
In our eleven patients with GA1, seven differentGCDH 
gene mutations including three reported previously were 
detected. Near about half (45%) of GCDH mutations 
occurred in exon7, other mutations occurred in exon8, 
10, 11 equally. P 248 L mutation in exon 7 as the most 
frequent GCDH gene mutation in our study was reported 
in Turkey and Italy before (13).Other reported mutation 
in exon 7 was F236 L (26).A 433 V mutation in exon11 
was reported from Spain (3). The last mutation T429M 
in exon11 was reported (27).G244 C in exon7, R294 Q 
in exon8 and N373 S in exon 10 were novel mutations 
in this study. GCDH gene mutation in patients with GA1 
in Khuzestan Province in southeastern of Iran revealed 
E181Q, S255L, R402G,in order of frequency, were 
responsible for this disorder in that region (28).R 402 
wasthe most common mutation in European patients with 
GA1 was not detected in our patients, too. More than half 
of our patients were Turkish and we detect four different 
mutations in their GCDH gene. GA1 is more prevalent in 
this ethnicity. We did not find any evidence to document 
genotype and clinical phenotype correlation, owing to 
high variation of the disease course among patients, as 
another study (4).
In Conclusion,GA1 is a heterogeneous rapid 
neurodegenerative disorder with available biochemical 
and genetic test to detect asymptomatic patients. 
Expanded newborn screening program is recommended 
in this country. More patients’ genetic analysis is 
required to know better about GDCH gene mutation 
Iranian patients with GA1. 
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